HomeCompareXBIOW vs DGRO

XBIOW vs DGRO: Dividend Comparison 2026

XBIOW yields 11.40% · DGRO yields 2.10%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 XBIOW wins by $10.9K in total portfolio value
10 years
XBIOW
XBIOW
● Live price
11.40%
Share price
$17.54
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$42.5K
Annual income
$2,326.31
Full XBIOW calculator →
DGRO
iShares Core Dividend Growth ETF
● Live price
2.10%
Share price
$70.18
Annual div
$1.47
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.6K
Annual income
$235.38
Full DGRO calculator →

Portfolio growth — XBIOW vs DGRO

📍 XBIOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXBIOWDGRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XBIOW + DGRO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XBIOW pays
DGRO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XBIOW
Annual income on $10K today (after 15% tax)
$969.21/yr
After 10yr DRIP, annual income (after tax)
$1,977.36/yr
DGRO
Annual income on $10K today (after 15% tax)
$178.14/yr
After 10yr DRIP, annual income (after tax)
$200.07/yr
At 15% tax rate, XBIOW beats the other by $1,777.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XBIOW + DGRO for your $10,000?

XBIOW: 50%DGRO: 50%
100% DGRO50/50100% XBIOW
Portfolio after 10yr
$37.0K
Annual income
$1,280.85/yr
Blended yield
3.46%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XBIOW buys
0
DGRO buys
9
PoliticianChamberTickerTypeAmountDate
Scott Mr Franklin🏢 House$DGRO▼ Sell$15,001 - $50,0002024-08-06
Kevin Hern🏢 House$DGRO▲ Buy$1,001 - $15,0002022-09-30
Kevin Hern🏢 House$DGRO▲ Buy$1,001 - $15,0002021-09-30
Kevin Hern🏢 House$DGRO▲ Buy$250,001 - $500,0002021-07-01
K. Michael Conaway🏢 House$DGRO▲ Buy$50,001 - $100,0002020-12-17
K. Michael Conaway🏢 House$DGRO▲ Buy$15,001 - $50,0002020-11-30
K. Michael Conaway🏢 House$DGRO▲ Buy$50,001 - $100,0002020-08-10
K. Michael Conaway🏢 House$DGRO▲ Buy$15,001 - $50,0002020-04-22
K. Michael Conaway🏢 House$DGRO▲ Buy$1,001 - $15,0002020-04-06
K. Michael Conaway🏢 House$DGRO▲ Buy$15,001 - $50,0002020-04-06
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXBIOWDGRO
Forward yield11.40%2.10%
Annual dividend / share$2.00$1.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$42.5K$31.6K
Annual income after 10y$2,326.31$235.38
Total dividends collected$17.2K$2.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: XBIOW vs DGRO ($10,000, DRIP)

YearXBIOW PortfolioXBIOW Income/yrDGRO PortfolioDGRO Income/yrGap
1← crossover$11,840$1,140.25$11,290$209.57+$550.00XBIOW
2$13,931$1,261.76$12,722$213.54+$1.2KXBIOW
3$16,293$1,387.43$14,314$217.18+$2.0KXBIOW
4$18,951$1,516.57$16,080$220.53+$2.9KXBIOW
5$21,926$1,648.49$18,040$223.59+$3.9KXBIOW
6$25,243$1,782.51$20,215$226.40+$5.0KXBIOW
7$28,928$1,917.94$22,627$228.96+$6.3KXBIOW
8$33,007$2,054.14$25,302$231.31+$7.7KXBIOW
9$37,508$2,190.46$28,268$233.44+$9.2KXBIOW
10$42,460$2,326.31$31,557$235.38+$10.9KXBIOW

XBIOW vs DGRO: Complete Analysis 2026

XBIOWStock

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Full XBIOW Calculator →

DGROETF

The iShares Core Dividend Growth ETF seeks to track the investment results of an index composed of U.S. equities with a history of consistently growing dividends.

Full DGRO Calculator →
📬

Get this XBIOW vs DGRO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XBIOW vs SCHDXBIOW vs JEPIXBIOW vs OXBIOW vs KOXBIOW vs MAINXBIOW vs VIGXBIOW vs NOBLXBIOW vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.